How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.

ABSTRACT:

Abstract

Venetoclax has transformed the therapeutic landscape of acute myeloid leukemia (AML). Hypomethylating agents with venetoclax (HMA-VEN) have significantly improved outcomes and have become the standard therapy for older/unfit patients with newly diagnosed AML and are comparable to intensive chemotherapy in salvage setting. Venetoclax with intensive chemotherapy have shown high response rates in both frontline and salvage setting in younger patients, and triplet combinations with HMA-VEN and FLT3 inhibitors have shown encouraging results in FLT3mut AML. While patients with NPM1mut, IDH1/2mut experience favorable outcomes, those with TP53mut and secondary AML may experience minimal benefit from the addition of venetoclax. Despite improved outcomes, severe cytopenias and infec

SUBMITTER: Maiti A 

PROVIDER: S-EPMC8785772 | biostudies-literature | 2022 Jan-Feb 01

REPOSITORIES: biostudies-literature